An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
VERDICT
The label
Markup
read at $61.32
Travere Therapeutics, Inc. holds its Markup at $61.32.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · does not pass the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-08-07
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 11 days
Price
$61.32
Valuation
N/A trailing · 11.27 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.04
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$61.32
N/A P/E · 11.27 fwd
Our fair value
$88.12
44% discount
Analyst target (avg)
$70.50
+15% to current
Target low $49.00Analyst target rangeTarget high $90.00
▲ current $61.32 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$61.32
you are here
Conservative
$88.12
+44%
Analyst avg
$70.50
+15%
Our fair value
$88.12
+44%
Analyst high
$90.00
+47%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
48.20%
Profit margin
-7.35%
Debt to equity
2,515.72
Analyst consensus
Strong Buy · 14 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✗ DOES NOT PASS
Why it fails. The problem is its debt ratio. Because both standards agree on this, it is a clear exclusion, not a borderline case.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is 54.3% of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashInterest-bearing cash and securities are 38.0% of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is 28.6% of assets, under the 49% limit.Pass
Revenue purityOnly 2.6% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Rare disease biotech still burns cash fast
Picture a doctor handing a patient one pill a day that might slow a rare kidney disease. That is the promise Travere is selling. Revenue is rising at 56 percent, the shares trade at just 11.7 times forward earnings, and the ethical screen gives a clean pass. Yet the company still posts a negative 4 percent profit margin and a minus 69 percent return on equity, so the business has yet to prove it can keep the cash flowing once the early launch spending fades.
We pass because the numbers do not add up to a durable edge. An unknown moat, continued losses and heavy reliance on a single product leave too much room for clinical or competitive setbacks. The 23 percent gap between the current price and our fair value looks attractive only if the losses turn into steady profits soon, which the present figures do not confirm.
Risk sits in the usual biotech traps: trial delays, pricing pressure and dilution if cash runs short. Even with fourteen analysts calling it a strong buy, the market is still waiting for proof that growth converts into real earnings. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in TVTX's space worth a look
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
TVTX trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 53% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 209%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (14 analysts) rates it strong buy, with a mean price target of $54. Entered 2026-07-18 · Accumulation
JOURNAL
The dated journal · newest first, never edited
2026-07-18Accumulation$52.04+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 53% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 209%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (14 analysts) rates it strong buy, with a mean price target of $54.
2026-07-03Accumulation$52.04+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Accumulation$52.04Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$43.51
+7.4%
·
$1,074
+7.4%
2 months
$28.96
+61.4%
·
$1,614
+61.4%
3 months
$27.55
+69.7%
·
$1,697
+69.7%
6 months
$35.01
+33.5%
·
$1,335
+33.5%
1 year
$15.13
+208.9%
·
$3,089
+208.9%
2 years
$7.27
+542.9%
·
$6,429
+542.9%
3 years
$16.67
+180.4%
·
$2,804
+180.4%
5 years
$15.09
+209.7%
·
$3,097
+209.7%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever TVTX does next, these words stay.
Travere Therapeutics, Inc. · TVTX · Markup · $61.32
Recorded 2026-08-07 · before the outcome · scored mechanically
